HemostOD awarded CHF 2 million Innosuisse grant to support key development milestones

HemostOD awarded CHF 2 million Innosuisse grant to support key development milestones

HemostOD awarded CHF 2 million Innosuisse grant to support key development milestones Lausanne, Switzerland — 03 February 2026 – HemostOD, a private Swiss company pioneering the ex vivo manufacturing of donor-free, off-the-shelf universal human blood platelets, today announced that it has been awarded a grant of CHF 2 million ($2.5 million) by Innosuisse, the Swiss Innovation Agency, to support the preclinical development of its donor-free unive…